申请人:S.A. Labaz N.V.
公开号:US04378362A1
公开(公告)日:1983-03-29
Novel indolizine derivatives represented by the general formula: ##STR1## and the pharmaceutically acceptable acid addition salts thereof, wherein: R represents an alkyl radical having from 1 to 8 carbon atoms, or a phenyl group non-substituted or bearing one or two substituents, selected from halogen atoms and from lower alkyl and alkoxy groups, X.sub.1 represents hydrogen, chlorine, bromine, iodine, methyl or methoxy, A represents a group selected from: ##STR2## in which X.sub.2 represents hydrogen, chlorine, bromine, iodine, methyl or methoxy and X.sub.3 represents hydrogen, chlorine, bromine, iodine or methyl, R.sub.1 represents a methyl, ethyl, n-propyl or n-butyl radical, n represents an integer in the range of 2 to 6 inclusive, with the proviso that when both X.sub.2 and X.sub.3 represent hydrogen or methyl, X.sub.1 is other than hydrogen. They are effective for treating pathological syndromes of the heart and particularly angina pectoris and cardiac arrhythmias.
新型吲哚啉衍生物的一般式表示为:##STR1##以及其药学上可接受的酸盐加成物,其中:R代表具有1至8个碳原子的烷基基团,或非取代或带有1或2个卤素原子、低烷基和烷氧基取代基的苯基;X.sub.1代表氢、氯、溴、碘、甲基或甲氧基;A代表选择自:##STR2##其中X.sub.2代表氢、氯、溴、碘、甲基或甲氧基,X.sub.3代表氢、氯、溴、碘或甲基,R.sub.1代表甲基、乙基、正丙基或正丁基基团,n代表在2到6之间的整数,条件是当X.sub.2和X.sub.3都代表氢或甲基时,X.sub.1不是氢。它们对于治疗心脏病理综合征,特别是心绞痛和心律失常非常有效。